Receiving a Deficiency Letter: Key Steps for the 90-Day Correction Period

1. Key takeaways

When a Deficiency Letter arrives, the response should be submitted complete, in one pass, inside the window stated in the letter. The industry working figure for that window is 30 days, while some sources cite 90 days. An incomplete response leads to a Letter of Disapproval (LOD), and at that point the file has to be re-applied for, paid for again and re-queued. GRZAN uses the shorter figure of 30 days as the internal response target regardless of which external figure applies.

• The response window should be read from the notice itself. Where practice references differ, the letter governs.
• Partial answers are treated as no answer. Every item has to be closed before the response is filed.
• A LOD resets the project: new application, new fee, new queue position, and the earlier cycle and fees are sunk.
• Most deficiency items are avoidable. They come from document preparation, not from the device itself.
• The sanction for a missed or incomplete response grows once the fee moratorium ends and AO 2024-0016 is restored in full.

2. Legal basis

The deficiency mechanism sits inside the review process established by Department of Health Administrative Order No. 2018-0002 of 26 January 2018, which sets a review period of 180 days from acceptance. The response window is not stated as a single fixed figure across the material we verified: the industry working figure is 30 days, and some sources state 90 days, so the deadline printed on the deficiency notice is the operative one. An incomplete response results in a Letter of Disapproval, after which the applicant must re-apply and pay again. Processing conduct is also subject to RA No. 11032.

3. Expert insights

Two figures circulate for the response window, and the letter decides. During verification we found both 30 days and 90 days cited in industry material. GRZAN’s rule is to take the deadline printed on the deficiency notice as controlling, and then to set the internal target at the stricter 30 days. The reasoning is simple: submitting early carries no penalty, while submitting late can move the file directly into the LOD process. An internal target that matches the most generous external reading of the rule is not a target, it is a gamble.

The response must be complete, not partial. The most common failure mode is a company that submits in a hurry just before the deadline having answered only some of the questions. From the regulator’s perspective that is equivalent to not responding at all. The correct method is to break the deficiency notice down item by item into a task list, assign each item an owner, a source of material and a completion date, and submit only when every item is closed and the closure is documented in the response letter.

High-frequency deficiency items can be eliminated before submission. The recurring list from GRZAN files includes: an ISO 13485 certificate whose scope does not cover the submitted product, which can be resolved by recertification or by extending the scope; a risk management report that is missing or does not match the device; clinical evidence that does not support the claimed intended use; labelling that contains Chinese characters or lacks mandatory elements, namely the registration number, the manufacturer and holder names and addresses, the country of origin, the lot or serial number, the manufacturing date and expiry, the sterilisation status, storage conditions, warnings and the intended use; an LOA without completed notarisation or Apostille; and inconsistency of model, product name or manufacturer name between documents. All six fall inside the scope of a pre-submission self-check.

A LOD costs far more than a proper response. Once a Letter of Disapproval is issued, the project returns to the starting line: re-application, re-payment, re-queuing, with the elapsed time and the official fees already spent treated as sunk. The cost grows further once the fee moratorium ends and AO 2024-0016 is applied in full, because re-application then carries the restored fee level. Getting the response right matters more than getting it out quickly, although a well-managed process usually achieves both.

4. Practical recommendations

• Break the letter into a task list on the day it arrives. Each deficiency item gets an owner, a source of evidence, a drafting deadline and a closure date, and the list is reviewed daily until submission.
• Set the internal target at 30 days rather than at the longest reading of the rule. The internal calendar should not assume the more generous window, because the notice may not allow it.
• Complete a cross pre-review 72 hours before submission. Someone who did not draft the response should check three things: whether every question has been answered in the same order as the letter, whether the supporting material is actually attached, and whether the new documents are consistent with the rest of the file.
• Run a deficiency rehearsal before the original submission. Use the high-frequency list to self-audit the file, so that the issues are resolved before the regulator raises them.
• Keep the response traceable. Reference each deficiency item number in the response, so that the reviewer does not have to reconstruct the mapping between question and answer.

5. Verification checklist

• □ Deadline stated in the notice has been read and recorded.
• □ Internal response target set at 30 days or less.
• □ Every deficiency item is closed and evidenced in the task list.
• □ ISO 13485 scope covers the submitted product.
• □ Risk management report matches the device and the applicable ISO 14971 content.
• □ Label is in English, complete, and free of Chinese characters.
• □ LOA authentication chain is intact: notarisation plus Apostille.
• □ Cross-document consistency checked for product name, model and manufacturer name.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com